Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 2, 23 | 0.08 Increased by +142.11% | 0.12 Decreased by -33.33% |
| May 3, 23 | -0.13 Increased by +38.10% | -0.11 Decreased by -18.18% |
| Mar 2, 23 | 0.06 Increased by +119.35% | 0.00 Increased by +6.09 K% |
| Nov 3, 22 | -0.14 Increased by +66.67% | -0.17 Increased by +17.65% |
| Aug 4, 22 | -0.19 Increased by +57.78% | -0.19 |
| May 5, 22 | -0.21 Increased by +38.24% | -0.22 Increased by +4.55% |
| Feb 28, 22 | -0.31 Increased by +3.13% | -0.30 Decreased by -3.33% |
| Nov 12, 21 | -0.42 Decreased by -110.00% | -0.35 Decreased by -20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 22.33 M Increased by +784.13% | -17.12 M Increased by +36.44% | Decreased by -76.66% Increased by +92.81% |
| Mar 31, 23 | 11.37 M Increased by +2.33 K% | -26.77 M Increased by +4.62% | Decreased by -235.49% Increased by +96.07% |
| Dec 31, 22 | 44.18 M Increased by +4.19 K% | 10.70 M Increased by +128.74% | Increased by +24.21% Increased by +100.67% |
| Sep 30, 22 | 4.99 M Increased by +325.06% | -23.91 M Increased by +45.15% | Decreased by -479.46% Increased by +87.10% |
| Jun 30, 22 | 2.53 M Increased by +92.38% | -26.94 M Increased by +40.39% | Decreased by -1.07 K% Increased by +69.01% |
| Mar 31, 22 | 468.00 K Decreased by -92.89% | -28.07 M Increased by +15.33% | Decreased by -6.00 K% Decreased by -1.09 K% |
| Dec 31, 21 | 1.03 M Decreased by -43.12% | -37.22 M Decreased by -28.89% | Decreased by -3.62 K% Decreased by -126.59% |
| Sep 30, 21 | 1.17 M Decreased by -56.76% | -43.59 M Decreased by -140.71% | Decreased by -3.72 K% Decreased by -456.72% |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.